About 7 results found for searched term "MMAF" (0.236 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M5041 | MMAF | Microtubule |
| Monomethylauristatin F | ||
| Monomethylauristatin F(MMAF) is an antitubulin agent that inhibit cell division by blocking the polymerization of tubulin; lower cytotoxic activity than MMAE; antibody compound cytotoxin.*The compound is unstable in solutions, freshly prepared is recommended | ||
| M10397 | McMMAF | Drug-Linker Conjugates for ADC |
| Maleimidocaproyl monomethylauristatin F | ||
| McMMAF is a protective group-conjugated MMAF. *The compound is unstable in solutions, freshly prepared is recommended | ||
| M10403 | MC-Val-Cit-PAB-MMAF | Drug-Linker Conjugates for ADC |
| MC-Val-Cit-PAB-MMAF is a drug-linker conjugate for ADC with antitumor activity by using the tubulin inhibitor, MMAF, linked via cathepsin cleavable MC-Val-Cit-PAB. | ||
| M13452 | MMAF-OMe | Others |
| Monomethyl auristatin F methyl ester | ||
| MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC50s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4-) cell lines, respectively. | ||
| M13692 | MMAF hydrochloride | Microtubule |
| Monomethylauristatin F hydrochloride | ||
| MMAF (Monomethylauristatin F) hydrochloride is a potent tubulin polymerization inhibitor and is used as a antitumor agent. | ||
| M57733 | MMAF intermediate 2 | Others |
| MMAF intermediate 2 | ||
| M58983 | Denintuzumab-MMAF | Antibody-Drug Conjugates (ADCs) |
| Anti-CD19 Reference Antibody | ||
| Denintuzumab-MMAF is an antibody-drug conjugate (ADC). Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
